[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3394259T3 - Sammensætninger og fremgangsmåder til reducering af tau-ekspression - Google Patents

Sammensætninger og fremgangsmåder til reducering af tau-ekspression Download PDF

Info

Publication number
DK3394259T3
DK3394259T3 DK16823350.0T DK16823350T DK3394259T3 DK 3394259 T3 DK3394259 T3 DK 3394259T3 DK 16823350 T DK16823350 T DK 16823350T DK 3394259 T3 DK3394259 T3 DK 3394259T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
tau expression
reducing tau
reducing
Prior art date
Application number
DK16823350.0T
Other languages
English (en)
Inventor
Ofengeim Manuela Polydoro
Jan Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3394259T3 publication Critical patent/DK3394259T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16823350.0T 2015-12-21 2016-12-19 Sammensætninger og fremgangsmåder til reducering af tau-ekspression DK3394259T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270165P 2015-12-21 2015-12-21
PCT/IB2016/057794 WO2017109679A1 (en) 2015-12-21 2016-12-19 Compositions and methods for decreasing tau expression

Publications (1)

Publication Number Publication Date
DK3394259T3 true DK3394259T3 (da) 2024-05-27

Family

ID=57758674

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16823350.0T DK3394259T3 (da) 2015-12-21 2016-12-19 Sammensætninger og fremgangsmåder til reducering af tau-ekspression

Country Status (42)

Country Link
US (2) US11473083B2 (da)
EP (2) EP4406541A3 (da)
JP (3) JP7027328B2 (da)
KR (1) KR20180089517A (da)
CN (2) CN109072237B (da)
AR (1) AR107579A1 (da)
AU (2) AU2016376034B2 (da)
BR (1) BR112018012304A2 (da)
CA (1) CA3008094A1 (da)
CL (3) CL2018001652A1 (da)
CO (1) CO2018006297A2 (da)
CR (1) CR20200609A (da)
CU (1) CU24574B1 (da)
DK (1) DK3394259T3 (da)
DO (1) DOP2018000151A (da)
EA (2) EA036417B1 (da)
EC (1) ECSP18050575A (da)
ES (1) ES2984631T3 (da)
FI (1) FI3394259T3 (da)
HK (1) HK1254822A1 (da)
HR (1) HRP20240672T1 (da)
HU (1) HUE066548T2 (da)
IL (3) IL305866B1 (da)
JO (2) JOP20200228A1 (da)
LT (1) LT3394259T (da)
MA (1) MA44426B1 (da)
MX (2) MX2018007726A (da)
MY (1) MY191737A (da)
PE (2) PE20241069A1 (da)
PH (1) PH12018501207A1 (da)
PL (1) PL3394259T3 (da)
PT (1) PT3394259T (da)
RS (1) RS65535B1 (da)
RU (1) RU2747734C2 (da)
SA (1) SA518391831B1 (da)
SG (2) SG11201804704PA (da)
SI (1) SI3394259T1 (da)
SV (1) SV2018005714A (da)
TW (2) TWI787163B (da)
UY (1) UY37038A (da)
WO (1) WO2017109679A1 (da)
ZA (1) ZA201803661B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203395A1 (en) 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
TWI657819B (zh) 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
MA52149A (fr) * 2018-03-13 2021-01-20 Janssen Pharmaceutica Nv Oligonucléotides modifiés et méthodes d'utilisation dans les tauopathies
JP7102557B2 (ja) 2018-07-03 2022-07-19 エフ．ホフマン－ラ ロシュ アーゲー Ｔａｕ発現調節用オリゴヌクレオチド
CA3178304A1 (en) * 2020-03-30 2021-10-07 Alnylam Pharmaceuticals, Inc. Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof
CN113817728A (zh) * 2020-06-19 2021-12-21 四川大学华西医院 一种有效干扰Tau蛋白表达的重组慢病毒及其应用
JP2024523265A (ja) * 2021-06-16 2024-06-28 エンピリコ インク． Ｍｔｒｅｓ１関連の疾患および障害の処置
WO2024091874A1 (en) * 2022-10-25 2024-05-02 Empirico Inc. Gene therapy treatment of mtres1 related diseases and disorders
WO2024155739A1 (en) * 2023-01-18 2024-07-25 Aptah Bio, Inc. Polynucleotide compositions and methods for treatment of neurodegenerative diseases
WO2024155740A1 (en) * 2023-01-18 2024-07-25 Aptah Bio, Inc. Polynucleotide compositions and methods for treatment of cancer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA2073500C (en) 1990-01-11 2008-03-25 Phillip Dan Cook Compositions and methods for detecting and modulating rna activity and gene expression
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US20020052331A1 (en) 1990-08-14 2002-05-02 Brenda Baker Compositions and methods for antisense inhibition of protein translation
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU681071B2 (en) 1991-12-06 1997-08-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Tools for the diagnosis and treatment of alzheimer's disease
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
NZ266386A (en) 1993-05-11 1997-11-24 Univ North Carolina Use of antisense rna oligonucleotides in regulating gene expression
TR199801581T2 (xx) 1996-02-14 1998-10-21 Isis Pharmaceuticals, Inc. �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler.
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
EP1557424A1 (en) 1997-09-12 2005-07-27 Exiqon A/S Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
WO1999057129A1 (en) 1998-05-01 1999-11-11 Mayo Foundation For Medical Education And Research Pathogeniv tau mutations
PL200772B1 (pl) * 1998-07-14 2009-02-27 Corixa Corp Izolowany polipeptyd, fuzja białkowa oraz ich zastosowanie, izolowany epitop komórki T, wektor ekspresyjny, komórka gospodarza, sposób stymulowania i/lub namnażania komórek T, izolowana populacja komórek T, kompozycja i jej zastosowanie oraz izolowane komórki T
ID30093A (id) 1999-02-12 2001-11-01 Sankyo Co Analog-analog nukleosida dan oligonukleotida baru
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6350868B1 (en) 1999-04-26 2002-02-26 University Of North Carolina At Chapel Hill Antisense human fucosyltransferase sequences and methods of use thereof
KR100782896B1 (ko) 1999-05-04 2007-12-06 엑시콘 에이/에스 Ｌ-리보-ｌｎａ 유사체
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
CN101284873A (zh) * 1999-06-30 2008-10-15 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
AU2001229619A1 (en) * 2000-01-21 2001-07-31 Pharmacia And Upjohn Company Transgenic mouse model of human neurodegenerative disease
EP1265999A2 (en) * 2000-02-28 2002-12-18 Decode Genetics EHF. Human schizophrenia gene
AU2002231741A1 (en) 2001-01-11 2002-07-24 Bayer Aktiengesellschaft Regulation of human tau-tubulin kinase
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
US20050130924A1 (en) 2002-06-26 2005-06-16 Monia Brett P. Antisense inhibition via RNAse H-independent reduction in mRNA
WO2004003134A2 (en) 2002-06-26 2004-01-08 Isis Pharmaceuticals, Inc. Antisense inhibition via rnase h-independent reduction in mrna
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
WO2004016655A1 (ja) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7906326B2 (en) 2003-05-07 2011-03-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof
US20070077553A1 (en) 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US20130130231A1 (en) 2002-11-26 2013-05-23 Isaac Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
RU2399671C2 (ru) 2003-08-28 2010-09-20 Новартис Аг Способный к интерференции дуплекс рнк, имеющий "тупые" концы и 3'-модификации
WO2005040382A2 (de) 2003-10-28 2005-05-06 Alexander Cherkasky Cherkasky - fusionsproteine enthaltend antikorperbinde-, antigenbinde - mikrotubulibinde und immunantwortauslosende
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
IL179285A (en) * 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
EP3808845A1 (en) 2004-06-28 2021-04-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US7312035B2 (en) 2004-09-03 2007-12-25 Affymetrix, Inc. Methods of genetic analysis of yeast
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
ES2540754T3 (es) 2004-12-03 2015-07-13 Rhode Island Hospital Diagnóstico y tratamiento de la Enfermedad de Alzheimer
US20070048756A1 (en) 2005-04-18 2007-03-01 Affymetrix, Inc. Methods for whole genome association studies
EP1937312B1 (en) 2005-08-30 2016-06-29 Ionis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
WO2007047913A2 (en) 2005-10-20 2007-04-26 Isis Pharmaceuticals, Inc Compositions and methods for modulation of lmna expression
GB0605337D0 (en) * 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
US7901882B2 (en) 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
EP2007889A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
WO2008002620A2 (en) 2006-06-27 2008-01-03 University Of Virginia Patent Foundation Cell model for alzheimer's disease pathology
JP2010509923A (ja) 2006-11-23 2010-04-02 ミルクス セラピューティクス アンパーツゼルスカブ 標的ｒｎａの活性を変化させるためのオリゴヌクレオチド
EP2578692B1 (en) 2007-04-05 2016-06-08 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
JP5773535B2 (ja) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物
KR20230137491A (ko) 2009-11-12 2023-10-04 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
US20150018223A1 (en) 2010-01-28 2015-01-15 University Of Massachusetts Lowell Methods of diagnosing tau-associated neurodegenerative diseases
WO2011117353A1 (en) 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
EP3260540A1 (en) 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
US9145557B2 (en) 2010-11-23 2015-09-29 Mirrx Therapeutics A/S Oligonucleotides for modulation of target RNA activity
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
US9957558B2 (en) * 2011-04-28 2018-05-01 Life Technologies Corporation Methods and compositions for multiplex PCR
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
AU2013203395A1 (en) * 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
JP2015518704A (ja) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 膜タンパク質の産生のための修飾ポリヌクレオチド
US20150104468A1 (en) 2012-06-04 2015-04-16 Irm Llc Site-specific labeling methods and molecules produced thereby
WO2014064187A1 (en) 2012-10-24 2014-05-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A microtubuli-modifying compound
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
KR20150099804A (ko) 2012-12-20 2015-09-01 사렙타 쎄러퓨틱스 인코퍼레이티드 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
AU2014236160A1 (en) 2013-03-14 2015-10-01 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
ES2807379T3 (es) * 2013-03-14 2021-02-22 Ionis Pharmaceuticals Inc Composiciones y métodos para regular la expresión de Tau
US20140329881A1 (en) 2013-03-14 2014-11-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US20160367587A1 (en) 2013-06-12 2016-12-22 Oncoimmunin, Inc. Systemic In Vivo Delivery of Oligonucleotides
TWI657819B (zh) * 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
WO2015068075A2 (en) 2013-10-24 2015-05-14 Institut National De La Sante Et De La Recherche Medicale Detection of tau
WO2016011123A1 (en) * 2014-07-16 2016-01-21 Arrowhead Research Corporation Organic compositions to treat apoc3-related diseases
US20170211064A1 (en) 2014-07-29 2017-07-27 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression
WO2016127000A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
EP3253875B1 (en) * 2015-02-04 2020-01-08 H. Hoffnabb-La Roche Ag Tau antisense oligomers and uses thereof
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
US20170035860A1 (en) * 2015-04-02 2017-02-09 Alexander C. Flynn Compositions and methods for treatment of neurogenerative diseases

Also Published As

Publication number Publication date
EA201891468A1 (ru) 2018-12-28
IL260124A (en) 2018-07-31
SV2018005714A (es) 2018-09-10
RU2018126545A (ru) 2020-01-23
JP2021118732A (ja) 2021-08-12
HRP20240672T1 (hr) 2024-08-16
ES2984631T3 (es) 2024-10-30
EP3394259A1 (en) 2018-10-31
CL2018001652A1 (es) 2018-08-10
CA3008094A1 (en) 2017-06-29
CL2019003420A1 (es) 2020-05-15
LT3394259T (lt) 2024-06-10
US20220411796A1 (en) 2022-12-29
IL296844B2 (en) 2024-04-01
RS65535B1 (sr) 2024-06-28
CU20180065A7 (es) 2018-11-06
CU24574B1 (es) 2022-01-13
JP2019500428A (ja) 2019-01-10
MX2018007726A (es) 2018-08-15
JOP20200228A1 (ar) 2017-06-16
PE20181448A1 (es) 2018-09-12
AU2020267282B2 (en) 2023-05-18
BR112018012304A2 (pt) 2019-02-05
AU2020267282A1 (en) 2020-12-10
UY37038A (es) 2017-07-31
CL2019000149A1 (es) 2019-06-07
MX2023008211A (es) 2023-07-18
SA518391831B1 (ar) 2022-08-16
PE20241069A1 (es) 2024-05-13
WO2017109679A1 (en) 2017-06-29
TWI834177B (zh) 2024-03-01
IL296844A (en) 2022-11-01
US20170175116A1 (en) 2017-06-22
HUE066548T2 (hu) 2024-08-28
EP3394259B1 (en) 2024-02-28
ZA201803661B (en) 2024-08-28
IL305866B1 (en) 2024-08-01
TW202311530A (zh) 2023-03-16
RU2021112980A3 (da) 2021-12-28
RU2018126545A3 (da) 2020-10-12
RU2021112980A (ru) 2021-05-28
AU2016376034A1 (en) 2018-07-05
SG10201913434PA (en) 2020-03-30
JP7027328B2 (ja) 2022-03-01
EP4406541A2 (en) 2024-07-31
EA202091865A1 (ru) 2021-01-29
JP2022065096A (ja) 2022-04-26
CR20200609A (es) 2021-02-17
AR107579A1 (es) 2018-05-16
JO3790B1 (ar) 2021-01-31
MA44426B1 (fr) 2024-05-31
CO2018006297A2 (es) 2018-07-10
FI3394259T3 (fi) 2024-05-24
KR20180089517A (ko) 2018-08-08
RU2747734C2 (ru) 2021-05-13
TW201733597A (zh) 2017-10-01
CN116218848A (zh) 2023-06-06
ECSP18050575A (es) 2018-07-31
CN109072237A (zh) 2018-12-21
PT3394259T (pt) 2024-05-20
SG11201804704PA (en) 2018-07-30
EA036417B1 (ru) 2020-11-09
HK1254822A1 (zh) 2019-07-26
CN109072237B (zh) 2022-12-16
PH12018501207A1 (en) 2019-02-11
MY191737A (en) 2022-07-13
AU2016376034B2 (en) 2020-12-03
IL296844B1 (en) 2023-12-01
DOP2018000151A (es) 2018-09-15
US11473083B2 (en) 2022-10-18
PL3394259T3 (pl) 2024-07-22
EP4406541A3 (en) 2024-10-16
TWI787163B (zh) 2022-12-21
IL305866A (en) 2023-11-01
SI3394259T1 (sl) 2024-07-31

Similar Documents

Publication Publication Date Title
DK3386534T3 (da) Sammensætninger og fremgangsmåder til internalisering af enzymer
DK3212778T3 (da) Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
DK3356529T3 (da) Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK4011887T3 (da) Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3316909T5 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3519572T3 (da) Forbindelser og fremgangsmåder til reduktion af tau-ekspression
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3402483T3 (da) Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
KR20180084891A (ko) 구조 조성물 및 방법
DK3262008T3 (da) Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3319948T3 (da) Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse
DK3322695T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase
DK3319609T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer
DK3319949T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder